Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jaip.2015.07.007DOI Listing

Publication Analysis

Top Keywords

drug rash
4
rash eosinophilia
4
eosinophilia systemic
4
systemic symptoms
4
symptoms caused
4
caused dietary
4
dietary supplement
4
supplement diindolylmethane
4
drug
1
eosinophilia
1

Similar Publications

Background: Isocitrate dehydrogenase (IDH) inhibitors hold promise for IDH-mutated cancer patients and demonstrated favorable clinical efficacy. Nonetheless, a comprehensive understanding of the associated toxicities of IDH inhibitors remains notably lacking.

Research Design And Methods: This pharmacovigilance analysis utilized the FDA Adverse Event Reporting System (FAERS) database to assess notable adverse events (AEs) attributed to IDH inhibitors (enasidenib and ivosidenib) from January 2018 to December 2023.

View Article and Find Full Text PDF

Practical recommendations for therapy and monitoring of mogamulizumab patients in Germany.

J Dtsch Dermatol Ges

December 2024

Department of Dermatology, Venereology, Allergology and Phlebology, Johannes Wesling Clinic, University Hospital of the Ruhr University Bochum, Bochum, Germany.

Mycosis fungoides (MF) and Sézary syndrome (SS) are the most common subtypes of the heterogeneous group of cutaneous T-cell lymphomas (CTCL). With the expansion of the biologic treatment landscape, new treatment options have become available in recent years, most notably the C-C chemokine receptor 4 (CCR4)-directed monoclonal antibody mogamulizumab. Based on the phase III pivotal trial, mogamulizumab is recommended by the German S2k guidelines for the second-line treatment of stage IB and above SS and MF, after at least one prior systemic therapy.

View Article and Find Full Text PDF

A 61-year-old woman underwent an open right hemicolectomy for perforated ascending colon cancer. Later, the patient underwent R2 surgery for duodenal invasion. Chemotherapy was initiated with mFOLFOX6 and panitumumab post-surgery.

View Article and Find Full Text PDF

Background: Systemic lupus erythematosus is a multi-organ autoimmune disorder that is treated by immunosuppressive agents that weaken the immune defense against opportunistic pathogens and latent infections such as strongyloidiasis. Herein, we report the case of a 43-year-old woman known to have systemic lupus erythematosus who presented with gastrointestinal symptoms, edema, and bone pain 2 months after receiving immunosuppressive treatment.

Case Presentation: A 43-year-old Iranian female known to have systemic lupus erythematosus and antiphospholipid syndrome presented with abdominal pain, nausea, vomiting, and generalized edema.

View Article and Find Full Text PDF

Clinical cues for distinguishing bullous fixed drug eruption from Stevens-Johnson syndrome: A case report.

SAGE Open Med Case Rep

December 2024

Department of Dermatology, KCU-GME Consortium/Advanced Dermatology and Cosmetic Surgery, Orlando, FL, USA.

This case report discusses two clinical encounters of a 62-year-old Hispanic woman initially hospitalized with suspected Stevens-Johnson syndrome, later correctly diagnosed with bullous fixed drug eruption during an outpatient visit for a similar eruption. The first encounter involved an extensive evaluation and an 11-day hospital stay, while the second was managed successfully as an outpatient with oral prednisone. This report highlights the importance of differentiating bullous fixed drug eruption from Stevens-Johnson syndrome/toxic epidermal necrolysis and emphasizes the need for a collaborative approach between Primary Care Providers and Dermatology to ensure optimal patient care.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!